ID   MMP3_RAT                Reviewed;         475 AA.
AC   P03957;
DT   23-OCT-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-1986, sequence version 1.
DT   24-JAN-2024, entry version 182.
DE   RecName: Full=Stromelysin-1;
DE            Short=SL-1;
DE            EC=3.4.24.17 {ECO:0000269|PubMed:1963430, ECO:0000269|PubMed:1988438, ECO:0000269|PubMed:2841336};
DE   AltName: Full=Matrix metalloproteinase-3;
DE            Short=MMP-3;
DE   AltName: Full=PTR1 protein;
DE   AltName: Full=Transin-1;
DE   Flags: Precursor;
GN   Name=Mmp3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3875482; DOI=10.1002/j.1460-2075.1985.tb03799.x;
RA   Matrisian L.M., Glaichenhaus N., Gesnel M.-C., Breathnach R.;
RT   "Epidermal growth factor and oncogenes induce transcription of the same
RT   cellular mRNA in rat fibroblasts.";
RL   EMBO J. 4:1435-1440(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2431284; DOI=10.1128/mcb.6.5.1679-1686.1986;
RA   Matrisian L.M., Gleroy P., Ruhlmann C., Gesnel M.-C., Breathnach R.;
RT   "Isolation of the oncogene and epidermal growth factor-induced transin
RT   gene: complex control in rat fibroblasts.";
RL   Mol. Cell. Biol. 6:1679-1686(1986).
RN   [3]
RP   PROTEIN SEQUENCE OF 19-28; 110-119; 309-315 AND 316-325, FUNCTION,
RP   CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=1963430; DOI=10.1093/oxfordjournals.jbchem.a123238;
RA   Umenishi F., Yasumitsu H., Ashida Y., Yamauti J., Umeda M., Miyazaki K.;
RT   "Purification and properties of extracellular matrix-degrading metallo-
RT   proteinase overproduced by Rous sarcoma virus-transformed rat liver cell
RT   line, and its identification as transin.";
RL   J. Biochem. 108:537-543(1990).
RN   [4]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION, DOMAIN,
RP   PROTEOLYTIC CLEAVAGE, ACTIVE SITE, AND MUTAGENESIS OF PRO-88; PRO-93;
RP   PHE-98; HIS-216; GLU-217 AND HIS-226.
RX   PubMed=2841336; DOI=10.1016/s0021-9258(18)37870-0;
RA   Sanchez-Lopez R., Nicholson R., Gesnel M.-C., Matrisian L.M.,
RA   Breathnach R.;
RT   "Structure-function relationships in the collagenase family member
RT   transin.";
RL   J. Biol. Chem. 263:11892-11899(1988).
RN   [5]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION, DOMAIN,
RP   PROTEOLYTIC CLEAVAGE, AND MUTAGENESIS OF MET-85; PRO-88; ARG-89; CYS-90;
RP   GLY-91; VAL-92 AND PRO-93.
RX   PubMed=1988438; DOI=10.1016/s0021-9258(18)52334-6;
RA   Park A.J., Matrisian L.M., Kells A.F., Pearson R., Yuan Z.Y., Navre M.;
RT   "Mutational analysis of the transin (rat stromelysin) autoinhibitor region
RT   demonstrates a role for residues surrounding the cysteine switch.";
RL   J. Biol. Chem. 266:1584-1590(1991).
CC   -!- FUNCTION: Can degrade fibronectin, laminin, gelatins of type I, III,
CC       IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans.
CC       Activates procollagenase. {ECO:0000269|PubMed:1963430}.
CC   -!- FUNCTION: Metalloproteinase with a rather broad substrate specificity
CC       that can degrade fibronectin, laminin, gelatins of type I, III, IV, and
CC       V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates
CC       different molecules including growth factors, plasminogen or other
CC       matrix metalloproteinases such as MMP9. Once released into the
CC       extracellular matrix (ECM), the inactive pro-enzyme is activated by the
CC       plasmin cascade signaling pathway. Acts also intracellularly. For
CC       example, in dopaminergic neurons, gets activated by the serine protease
CC       HTRA2 upon stress and plays a pivotal role in DA neuronal degeneration
CC       by mediating microglial activation and alpha-synuclein/SNCA cleavage.
CC       In addition, plays a role in immune response and possesses antiviral
CC       activity against various viruses. Mechanistically, translocates from
CC       the cytoplasm into the cell nucleus upon virus infection to influence
CC       NF-kappa-B activities. {ECO:0000250|UniProtKB:P08254}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Preferential cleavage where P1', P2' and P3' are hydrophobic
CC         residues.; EC=3.4.24.17; Evidence={ECO:0000269|PubMed:1963430,
CC         ECO:0000269|PubMed:1988438, ECO:0000269|PubMed:2841336};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:1963430};
CC       Note=Binds 4 Ca(2+) ions per subunit. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by a synthetic peptide corresponding to
CC       the inhibitory cysteine switch motif (PubMed:1988438). Inhibited by
CC       ethylenediaminetetraacetic acid (EDTA), 1,10-pheanthroline, 2-
CC       mecaptoethanol, dithiothreitol and metalloproteinase inhibitor protein
CC       TIMP (PubMed:1963430, PubMed:2841336). {ECO:0000269|PubMed:1963430,
CC       ECO:0000269|PubMed:1988438, ECO:0000269|PubMed:2841336}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000305}. Secreted {ECO:0000269|PubMed:1963430,
CC       ECO:0000269|PubMed:1988438, ECO:0000269|PubMed:2841336}.
CC   -!- INDUCTION: By epidermal growth factor and is increased in FR3T3 and
CC       RAT-1 fibroblasts transformed by polyoma virus, Rous sarcoma virus, or
CC       the human cellular H-Ras oncogene.
CC   -!- DOMAIN: The conserved cysteine present in the cysteine-switch motif
CC       binds the catalytic zinc ion, thus inhibiting the enzyme. The
CC       dissociation of the cysteine from the zinc ion upon the activation-
CC       peptide release activates the enzyme. {ECO:0000269|PubMed:1988438,
CC       ECO:0000269|PubMed:2841336}.
CC   -!- SIMILARITY: Belongs to the peptidase M10A family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02601; CAA26448.1; -; mRNA.
DR   PIR; A00997; KCRTIH.
DR   AlphaFoldDB; P03957; -.
DR   SMR; P03957; -.
DR   STRING; 10116.ENSRNOP00000012310; -.
DR   MEROPS; M10.005; -.
DR   MoonProt; P03957; -.
DR   GlyCosmos; P03957; 1 site, No reported glycans.
DR   GlyGen; P03957; 1 site.
DR   PhosphoSitePlus; P03957; -.
DR   ABCD; P03957; 1 sequenced antibody.
DR   UCSC; RGD:621317; rat.
DR   AGR; RGD:621317; -.
DR   RGD; 621317; Mmp3.
DR   InParanoid; P03957; -.
DR   PhylomeDB; P03957; -.
DR   Reactome; R-RNO-1442490; Collagen degradation.
DR   Reactome; R-RNO-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-RNO-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-RNO-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-RNO-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-RNO-9009391; Extra-nuclear estrogen signaling.
DR   PRO; PR:P03957; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0044297; C:cell body; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0031012; C:extracellular matrix; IEA:InterPro.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0004175; F:endopeptidase activity; ISO:RGD.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IBA:GO_Central.
DR   GO; GO:0008237; F:metallopeptidase activity; ISO:RGD.
DR   GO; GO:0008233; F:peptidase activity; ISS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; ISO:RGD.
DR   GO; GO:0071460; P:cellular response to cell-matrix adhesion; IEP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; ISO:RGD.
DR   GO; GO:0071492; P:cellular response to UV-A; ISS:UniProtKB.
DR   GO; GO:0030574; P:collagen catabolic process; IBA:GO_Central.
DR   GO; GO:0030198; P:extracellular matrix organization; IBA:GO_Central.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:RGD.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; ISO:RGD.
DR   GO; GO:0030163; P:protein catabolic process; ISO:RGD.
DR   GO; GO:0006508; P:proteolysis; ISO:RGD.
DR   GO; GO:0030334; P:regulation of cell migration; ISO:RGD.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0070555; P:response to interleukin-1; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEP:RGD.
DR   CDD; cd00094; HX; 1.
DR   CDD; cd04278; ZnMc_MMP; 1.
DR   Gene3D; 3.40.390.10; Collagenase (Catalytic Domain); 1.
DR   Gene3D; 2.110.10.10; Hemopexin-like domain; 1.
DR   InterPro; IPR000585; Hemopexin-like_dom.
DR   InterPro; IPR036375; Hemopexin-like_dom_sf.
DR   InterPro; IPR018487; Hemopexin-like_repeat.
DR   InterPro; IPR018486; Hemopexin_CS.
DR   InterPro; IPR033739; M10A_MMP.
DR   InterPro; IPR024079; MetalloPept_cat_dom_sf.
DR   InterPro; IPR001818; Pept_M10_metallopeptidase.
DR   InterPro; IPR021190; Pept_M10A.
DR   InterPro; IPR021158; Pept_M10A_Zn_BS.
DR   InterPro; IPR006026; Peptidase_Metallo.
DR   InterPro; IPR002477; Peptidoglycan-bd-like.
DR   InterPro; IPR036365; PGBD-like_sf.
DR   PANTHER; PTHR10201; MATRIX METALLOPROTEINASE; 1.
DR   PANTHER; PTHR10201:SF215; STROMELYSIN-1; 1.
DR   Pfam; PF00045; Hemopexin; 4.
DR   Pfam; PF00413; Peptidase_M10; 1.
DR   Pfam; PF01471; PG_binding_1; 1.
DR   PIRSF; PIRSF001191; Peptidase_M10A_matrix; 1.
DR   PRINTS; PR00138; MATRIXIN.
DR   SMART; SM00120; HX; 4.
DR   SMART; SM00235; ZnMc; 1.
DR   SUPFAM; SSF50923; Hemopexin-like domain; 1.
DR   SUPFAM; SSF55486; Metalloproteases ('zincins'), catalytic domain; 1.
DR   SUPFAM; SSF47090; PGBD-like; 1.
DR   PROSITE; PS00546; CYSTEINE_SWITCH; 1.
DR   PROSITE; PS00024; HEMOPEXIN; 1.
DR   PROSITE; PS51642; HEMOPEXIN_2; 4.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   Calcium; Collagen degradation; Direct protein sequencing; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Metalloprotease; Protease; Reference proteome; Repeat;
KW   Secreted; Signal; Zinc; Zymogen.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000305"
FT   PROPEP          18..97
FT                   /note="Activation peptide"
FT                   /evidence="ECO:0000303|PubMed:2841336"
FT                   /id="PRO_0000028734"
FT   CHAIN           98..475
FT                   /note="Stromelysin-1"
FT                   /id="PRO_0000028735"
FT   REPEAT          285..334
FT                   /note="Hemopexin 1"
FT   REPEAT          335..381
FT                   /note="Hemopexin 2"
FT   REPEAT          383..431
FT                   /note="Hemopexin 3"
FT   REPEAT          432..475
FT                   /note="Hemopexin 4"
FT   MOTIF           88..95
FT                   /note="Cysteine switch"
FT                   /evidence="ECO:0000269|PubMed:1988438,
FT                   ECO:0000269|PubMed:2841336"
FT   ACT_SITE        217
FT                   /evidence="ECO:0000269|PubMed:2841336"
FT   BINDING         90
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /note="in inhibited form"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         122
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         156
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         166
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         168
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         173
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         174
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         176
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         178
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         181
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         188
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         190
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         192
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         194
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         196
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         197
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         199
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         199
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         216
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         220
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         226
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         295
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         387
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   BINDING         436
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000250|UniProtKB:P03956"
FT   CARBOHYD        118
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        288..475
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         85
FT                   /note="M->L: Does not induce autoproteolytic activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         88
FT                   /note="P->A: Does not induce autoproteolytic activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         88
FT                   /note="P->G,L: Induces partial autoproteolytic activation."
FT                   /evidence="ECO:0000269|PubMed:1988438,
FT                   ECO:0000269|PubMed:2841336"
FT   MUTAGEN         89
FT                   /note="R->K,L,Q: Induces constitutive autoproteolytic
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         90
FT                   /note="C->S,H,D: Induces constitutive autoproteolytic
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         91
FT                   /note="G->A: Induces constitutive autoproteolytic
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         92
FT                   /note="V->G: Induces constitutive autoproteolytic
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         92
FT                   /note="V->I,A: Induces partial autoproteolytic activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         92
FT                   /note="V->L,D: Does not induce autoproteolytic activation."
FT                   /evidence="ECO:0000269|PubMed:1988438"
FT   MUTAGEN         93
FT                   /note="P->V,G,N: Induces partial autoproteolytic
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:1988438,
FT                   ECO:0000269|PubMed:2841336"
FT   MUTAGEN         98
FT                   /note="F->S: Loss of autocleavage without affecting
FT                   activation by APMA."
FT                   /evidence="ECO:0000269|PubMed:2841336"
FT   MUTAGEN         216
FT                   /note="H->L: Loss of autoproteolytic activation and
FT                   catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:2841336"
FT   MUTAGEN         217
FT                   /note="E->G: Loss of autoproteolytic activation and
FT                   catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:2841336"
FT   MUTAGEN         226
FT                   /note="H->S: Loss of autoproteolytic activation and
FT                   catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:2841336"
SQ   SEQUENCE   475 AA;  53428 MW;  D81239DC3E26782E CRC64;
     MKGLPVLLWL CTAVCSSYPL HGSEEDAGME VLQKYLENYY GLEKDVKQFT KKKDSSPVVK
     KIQEMQKFLG LKMTGKLDSN TMELMHKPRC GVPDVGGFST FPGSPKWRKN HISYRIVNYT
     LDLPRESVDS AIERALKVWE EVTPLTFSRI SEGEADIMIS FAVEEHGDFI PFDGPGMVLA
     HAYAPGPGTN GDAHFDDDER WTDDVTGTNL FLVAAHELGH SLGLFHSANA EALMYPVYKS
     STDLARFHLS QDDVDGIQSL YGPPTESPDV LVVPTKSNSL DPETLPMCSS ALSFDAVSTL
     RGEVLFFKDR HFWRKSLRTP EPGFYLISSF WPSLPSNMDA AYEVTNRDTV FILKGNQIWA
     IRGHEELAGY PKSIHTLGLP ETVQKIDAAI SLKDQKKTYF FVEDKFWRFD EKKQSMDPEF
     PRKIAENFPG IGTKVDAVFE AFGFLYFFSG SSQLEFDPNA GKVTHILKSN SWFNC
//
